Literature DB >> 8200007

Low frequency of the p53 gene mutations in neuroblastoma.

G Hosoi1, J Hara, T Okamura, Y Osugi, S Ishihara, M Fukuzawa, A Okada, S Okada, A Tawa.   

Abstract

BACKGROUND: The p53 gene frequently is affected by point mutations, rearrangements, or deletions that contribute to the genesis or progression of a wide variety of human adult solid tumors; however, to the authors' knowledge, this gene alteration has not been analyzed in neuroblastoma.
METHODS: Genomic DNA samples from 20 children with neuroblastoma, including 16 patients with advanced disease, were screened for the presence of mutations in exons 5-9 of the p53 gene, where over 90% of mutations have been reported to be located in human cancer. The screening technique employed polymerase chain reaction/single-strand conformation polymorphism analysis followed by direct DNA sequencing.
RESULTS: Heterozygous mutations were detected in 2 of the 20 cases. A silent mutation (T to G transversion) at codon 172 and a missense mutation (G to T transversion) at codon 259 were found in patients with Stage II and Stage IV disease, respectively. Thus, p53 mutations were found to occur in neuroblastoma, but at a low frequency (2 of 20).
CONCLUSIONS: Our data suggest that in a minority of neuroblastomas, p53 gene mutations may play a contributing role in tumorigenesis, but other genes presumably play a major role in this tumor.

Entities:  

Mesh:

Year:  1994        PMID: 8200007     DOI: 10.1002/1097-0142(19940615)73:12<3087::aid-cncr2820731230>3.0.co;2-9

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  27 in total

Review 1.  Therapeutic targets for neuroblastomas.

Authors:  Garrett M Brodeur; Radhika Iyer; Jamie L Croucher; Tiangang Zhuang; Mayumi Higashi; Venkatadri Kolla
Journal:  Expert Opin Ther Targets       Date:  2014-01-06       Impact factor: 6.902

2.  Targeted expression of MYCN causes neuroblastoma in transgenic mice.

Authors:  W A Weiss; K Aldape; G Mohapatra; B G Feuerstein; J M Bishop
Journal:  EMBO J       Date:  1997-06-02       Impact factor: 11.598

3.  High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma.

Authors:  Jane Carr-Wilkinson; Kieran O'Toole; Katrina M Wood; Christine C Challen; Angela G Baker; Julian R Board; Laura Evans; Michael Cole; Nai-Kong V Cheung; Joachim Boos; Gabriele Köhler; Ivo Leuschner; Andrew D J Pearson; John Lunec; Deborah A Tweddle
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

Review 4.  Antiangiogenesis as a novel therapeutic concept in pediatric oncology.

Authors:  L Schweigerer
Journal:  J Mol Med (Berl)       Date:  1995-10       Impact factor: 4.599

5.  The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization.

Authors:  S C Goldman; C Y Chen; T J Lansing; T M Gilmer; M B Kastan
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

6.  p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells.

Authors:  D A Tweddle; A J Malcolm; M Cole; A D Pearson; J Lunec
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

7.  The MYCN oncogene is a direct target of miR-34a.

Authors:  J S Wei; Y K Song; S Durinck; Q-R Chen; A T C Cheuk; P Tsang; Q Zhang; C J Thiele; A Slack; J Shohet; J Khan
Journal:  Oncogene       Date:  2008-05-26       Impact factor: 9.867

8.  MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model.

Authors:  Etienne Blanc; David Goldschneider; Eric Ferrandis; Michel Barrois; Gwenaëlle Le Roux; Stéphane Leonce; Sétha Douc-Rasy; Jean Bénard; Gilda Raguénez
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

Review 9.  Genetic susceptibility to neuroblastoma: current knowledge and future directions.

Authors:  Laura E Ritenour; Michael P Randall; Kristopher R Bosse; Sharon J Diskin
Journal:  Cell Tissue Res       Date:  2018-03-27       Impact factor: 5.249

10.  A novel 1p36.2 located gene, APITD1, with tumour-suppressive properties and a putative p53-binding domain, shows low expression in neuroblastoma tumours.

Authors:  C Krona; K Ejeskär; H Carén; F Abel; R-M Sjöberg; T Martinsson
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.